682 related articles for article (PubMed ID: 24444171)
1. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
3. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
4. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.
Narula N; Charleton D; Marshall JK
Aliment Pharmacol Ther; 2013 Jun; 37(11):1057-64. PubMed ID: 23581515
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Peyrin-Biroulet L; Deltenre P; de Suray N; Branche J; Sandborn WJ; Colombel JF
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):644-53. PubMed ID: 18550004
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
11. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
Ford AC; Peyrin-Biroulet L
Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
13. [Main therapeutic advances in IBD in 2007].
Felley C; Mottet C; Maillard MH; Hess J; Delarive J; Michetti P
Rev Med Suisse; 2008 Jan; 4(141):200, 202-4, 206-8 passim. PubMed ID: 18335885
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
Luthra P; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
16. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
17. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
18. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
Danese S
Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
[No Abstract] [Full Text] [Related]
19. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
20. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]